



Message to Patients Enrolled in The ATTeST Clinical Trial

This message is for caregivers and for all the people who live with AT who have participated and are participating in the ATTeST trial.

We at EryDel, as the ATTeST trial sponsor, want to thank you for your participation in the ATTeST trial. Together, we are all trying to make a difference in the lives of those people who live with AT by making a personal contribution to the largest clinical study ever in AT.

The spread of COVID-19, the disease caused by the new coronavirus, has disrupted everyone's daily life and in some cases resulted in the tragic loss of life. We are providing here some information regarding the ATTeST trial and will update this page regularly with new information if available.

1. What is the status of the ATTeST clinical trial?
 - a. The ATTeST trial is ongoing, and we are very close to full enrollment. EryDel will be as flexible and pragmatic as possible with regards to clinical trial requirements during this time.
2. Will the ATTeST trial continue over the next few months?
 - a. The safety of our study participants and their families as well as the site providers is always our priority, and this will guide our decisions with the Trial as events unfold. EryDel is in constant contact with the clinical study team at all sites and together we are constantly monitoring the situation.
 - b. We plan to continue the trial while at the same time acknowledging that sometimes there may have to be creative solutions for treatment visits as well as the amount of information collected, and EryDel is making its best effort to support the trial with remote support for sites. For example, EryDel has worked with its suppliers to ensure the supply of materials for ATTeST is sufficient. Also, in situations where public transportation is restricted, EryDel has worked with the study center to provide taxis free of charge.
3. What happens to my place in the trial if there is a delay and the delay is longer than expected?
 - a. We are doing our best to allow for the continuity of therapy with the sites to allow the study to continue for all participants, taking into consideration the safety of the patients and the value of collecting the data.
4. Will there be any negative medical ramifications for my health if the trial is delayed and I cannot continue to receive therapy?
 - a. Our expectation is that for a successful treatment, monthly infusions are required. It would be therefore ideal, if those treatments do continue to happen monthly or even every three weeks. Given the pandemic however, it is clear that at least some sites will not be able to secure these treatment intervals for a period of time. From a medical perspective, it would be desirable, if treatment visits in those cases are rescheduled as quickly as possible following the hopeful lifting of restrictions.

Headquarters & Registered office

via Antonio Meucci, 3
20091 Bresso (MI)
Italy
Tel.: +39 02 36504470
Fax: +39 02 36504473

Manufacturing plant

via Statale, 135
41036 Medolla (MO)
Italy
Tel.: +39 0535 1948160



5. If there is a delay, what will the impact be on the collection of information on the experience of people in the trial including on tests for how the drug may affect them data collection and subsequent potential approval of the therapy?
 - a. We will be discussing this with the FDA/EMA and other regulatory agencies as appropriate to determine the best course of action about evaluation of the study to meet the regulatory conditions for approval.
6. Within the coming weeks, we will add more information about the trial and you can find updates on our website www.attest-trial.com.
 - a. In the meantime, if you have any questions for EryDel, please contact your trial site and they will relay those question to EryDel. EryDel will respond to your physician and other clinical team members at the site as quickly as possible

Guidelines provided by your national health authorities and governments should be followed as the situation and the management might differ from one country to another. The situation is changing all the time and we advise you to monitor for the latest advice applicable to your area. We should stress the fact that only your physician and/or your AT clinical experts would know best what to recommend to you.

Below are COVID-19 Medical Resources

AT Society, UK

Latest news on corona virus

<https://www.atsociety.org.uk/living-with-at/covid-19-virus-coronavirus/>

AT CHILDREN'S PROJECT

COVID-19: Advice for AT Families

<https://www.atcp.org/covid-19-advice-for-a-t-families/>

Child Neurology Foundation

<https://www.childneurologyfoundation.org/cnf-cns-joint-official-response-to-covid-19/>

National Health Council

<https://nationalhealthcouncil.org/coronavirus-preparedness-for-people-with-chronic-diseases/>

Headquarters & Registered office

via Antonio Meucci, 3
20091 Bresso (MI)
Italy
Tel.: +39 02 36504470
Fax: +39 02 36504473

Manufacturing plant

via Statale, 135
41036 Medolla (MO)
Italy
Tel.: +39 0535 1948160